

Anti-CD20 Monoclonal Antibodies: Market Research Report

<https://marketpublishers.com/r/AD78081F223EN.html>

Date: July 2010

Pages: 432

Price: US\$ 3,950.00 (Single User License)

ID: AD78081F223EN

Abstracts

This report analyzes the Global market for Anti-CD20 Monoclonal Antibodies in US\$ Million.

Annual estimates and forecasts are provided for the period 2006 through 2015.

The report profiles 38 companies including many key and niche players such as Bayer Schering Pharma AG, Biocon, Biogen Idec, Inc., Eli Lilly and Company, F.Hoffmann-la Roche Ltd., Genentech, Inc., Genmab A/S, GlaxoSmithKline Plc, GTC Biotherapeutics, Inc., Immunomedics, Inc., InNexus Biotechnology, Inc., LFB Group, Nycomed, Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Trubion Pharmaceuticals, Inc., and UCB Pharmaceutical.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.MARKET OVERVIEW

Current and Future Analysis
Monoclonal Antibody Market Garner Riches
Rituxan/MabThera to Remain the Market Leader
Rituxan's Success Spurs Development of New Anti-CD20 Antibodies
Clinical Trial Failures Trouble Drug Makers, Retracts Market Growth
Safety Issues Mar Penetration of Radiolabelled CD20 Antibodies
Oncologists Resort to Zevalin and Bexxar As a Last Resort
Novel Action Mechanisms Bode Potential for New CD20 mAbs
Future of mAbs – Smaller and Inexpensive to Produce
Structurally Modified Full-Size mAbs – Next Type of mAbs to Hit the Market
MAb Fragments
Major Companies in the Chase for New-Generation Technologies
Next Generation CD20 mAbs
Comparison of Marketed and Pipeline CD20 Antibodies Based on Action Mechanism
Second Generation CD20 Antibodies
Ofatumumab
Veltuzumab
Ocrelizumab
Third Generation CD20 Antibodies
AME133v
TRU-015
GA101/Obinutuzumab
Incidence and Prevalence of Major Targeted Indications of CD20 mAbs
Rheumatoid Arthritis – A Chronic, Debilitating Disease
Incidence and Prevalence Higher in Urban and Developed Regions

Lymphoma Incidence and Mortality Rates On the Rise
Incidence of Hodgkin's Lymphoma - High in West Asia

Table 1. Age-Standardized Incidence Rates for Hodgkin's Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart)

Table 2. Age-Standardized Mortality Rates for Hodgkin's Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart)

2.MARKET DYNAMICS

PML Risks Clipping Label Expansions of Rituxan
Rituxan and Ocrelizumab Show Promise in RRMS Treatment
Ocrelizumab's Ouster in RA Puts Development Partners in a Quandary
Zevalin and Bexxar Sales Remain in Obscurity
The Road Ahead for Zevalin

3.FOCUS ON SELECT ANTI-CD20 MABS AVAILABLE WORLDWIDE

Approved Anti-CD20 Antibodies in a Nutshell
Select Anti-CD20 Antibodies' Pipeline in a Nutshell
Drug Details
Rituxan/MabThera (Biogen, Roche and Genentech)
Approved and Potential Indications for Rituxan
Zevalin (Spectrum™ Pharmaceuticals)
Bexxar (GlaxoSmithKline)
Ofatumumab (Genmab and GlaxoSmithKline)
Clinical Development of HuMax-CD20 by Indication and Stage of Development
Ocrelizumab (Biogen/Genentech)
Summary of Ocrelizumab Development Status
GA-101 (Roche/GlycArt)
TRU-015 (Trubion)
AME-133v (Eli Lilly)
Veltuzumab (Immunomedics/Nycomed)
Clinical Trials of Veltuzumab
BVX-20 (Biocon)
LFB-R603 (LFB Biotechnologies)
DXL625 (InNexus)

4.PRODUCT OVERVIEW

CD20 Antibody

Immune System: Natural Defenders

Human Antibodies

Types of Monoclonal Antibodies

Table 3. Worldwide mAb Market By Product Type (2008): Percentage Share Breakdown For Chimeric, Humanized, Human And Murine (includes corresponding Graph/Chart)

Chimeric Antibodies: Show Lesser Antigenicity

Murine Monoclonal Antibodies

Humanized Antibodies/ CDR Grafted Antibodies (Human Antibodies)

Fully Human Antibodies

Bispecific Antibodies

5.A PEEK INTO MONOCLOAL ANTIBODY MARKET

Evolution of Monoclonal Antibodies – A Historical Journey

Market Perspective of mAbs

Regional Perspective

Significant Growth Awaits mAbs

Shift Towards Humanized and Fully Human Antibodies

Ageing Baby Boomers Spur MABs Growth

Non-Existent Generic Competition Favors MAb Market

Rising Number of MABs Under Clinical Trials

High Costs Impede MABs Penetration

Opportunities in Technology Development

Advancements & Challenges in Antibody Production Processes

Increasing Demand for Protein A in MAB Manufacturing

6.RECENT DRUG APPROVALS AND REGULATORY STATUS

Rituxan Receives FDA Approval for the Treatment of Chronic Lymphocytic Leukemia

GSK Receives Positive Opinion for Arzerra™ from EMEA

LFB Obtains Orphan Drug Status for LFB-R603 in Europe

FDA Grants Accelerated Approval for GSK and Genmab's Ofatumumab for Chronic Lymphocytic Leukemia

InNexus's DXL625 Receives Positive Opinion from FDA

Spectrum Pharma Obtains FDA Approval for Zevalin's Expanded Label in NHL Treatment

Bayer Schering Obtains EU Approval for Zevalin in First-Line Treatment

7.RECENT INDUSTRY ACTIVITY

Pfizer Discontinues Development of TRU-015; Continues to Develop SBI-087

Roche and Biogen Discontinue Ocrelizumab Development in Rheumatoid Arthritis

Roche and Biogen File Patent Suit Against GSK

Ocrelizumab Meets Primary End-Point In Phase III Trial for RA

Rituxan Plus FC Chemotherapy Shows Improved Survival in Treatment-Naïve CLL Patients

FDA Declines Early Use of Rituxan in RA

LG Life Sciences Announces New Anti-CD20 Antibody Program

Provenance Acquires Global Rights to New Anti-CD20 Antibody from Merck

Roche Takes Over Genentech

Pfizer Acquires Wyeth

Spectrum Pharma Acquires Lymphoma Drug Zevalin

Biogen Partners with Genentech and Roche for Development of GA-101

Roche, GlycArt and Genentech Team Up for Development of GA-101

InNexus Biotechnology Discovers New Anti-CD20 Antibody, DXLr120

MRC Completes Humanization of Biolex's Anti-CD20 Antibody, BLX-301

Immunomedics Inks Licensing and Collaboration Deal with Nycomed

Rituxan Fails To Meet Primary End-Point in Phase II/III Trial for SLE

Rituxan Fails To Meet Primary End-Point in Phase II/III Trial for PPMS

Rituxan Meets Primary End-point in Phase III Trial for DMARD Inadequate Responders in RA

Cell Therapeutics Acquires Zevalin from Biogen Idec

InNexus Develops Dxl625 Anti-Cd20 Monoclonal Antibody

GTC and LFB Commence Development of Novel Anti-CD20 Antibody

Favrille Purchases Anti-CD20 mAbs from Diversa

Genmab and GSK Ink Global Collaboration Agreement for HuMax-CD20

8.FOCUS ON SELECT MARKET PARTICIPANTS

Bayer Schering Pharma AG (Germany)

Biocon (India)
Biogen Idec, Inc. (US)
Eli Lilly and Company (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Genentech, Inc. (US)
Genmab A/S (Denmark)
GlaxoSmithKline Plc. (UK)
GTC Biotherapeutics, Inc. (US)
Immunomedics, Inc. (US)
InNexus Biotechnology, Inc. (Canada)
LFB Group (France)
Nycomed (Switzerland)
Pfizer, Inc. (US)
Spectrum Pharmaceuticals, Inc. (US)
Trubion Pharmaceuticals, Inc.
UCB Pharmaceutical (Belgium)

9. GLOBAL MARKET PERSPECTIVE

Table 4. World Recent Past, Current & Future Analysis for Anti-CD20 Monoclonal Antibodies Market by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 5. World 10-year Perspective for Anti-CD20 Antibodies Market by Geographic Region – Percentage Breakdown of Value Sales for US and Rest of World Markets for Years 2006, 2010 & 2015

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 38 (including Divisions/Subsidiaries - 44)

Region/Country Players

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)

I would like to order

Product name: Anti-CD20 Monoclonal Antibodies: Market Research Report

Product link: <https://marketpublishers.com/r/AD78081F223EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AD78081F223EN.html>